Latuda for adhd

The Dopamine Dilemma - PMC

1. Olfson M, Gameroff M, Marcus S, Jensen P. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2003;160:1071–1077. [PubMed] [Google Scholar]

2. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6(2):79–83. [PubMed] [Google Scholar]

3. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among US children. Am J Psychiatry. 2006;1(3):579–585. [PubMed] [Google Scholar]

4. Bhatara V, Feil M, Hoagwood K, Vitiello B, Zima B. National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge. J Atten Disord. 2004;7(4):217–26. [PubMed] [Google Scholar]

5. Wonodi I, Reeves G, Carmichael D, et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord. 2007;22:1777–1782. [PubMed] [Google Scholar]

6. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679–685. [PubMed] [Google Scholar]

7. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2008;283(8):1025–1030. 23. [PubMed] [Google Scholar]

8. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;4(1):11–28. [PubMed] [Google Scholar]

9. Pliszka S, Crimson M, Hughes C, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. ACAP. 2006;45(6):642–657. [PubMed] [Google Scholar]

10. Stahl SM. Stahl's Essential Psychopharmacology. New York, NY: Cambridge University Press; 2008. pp. 878–879. [Google Scholar]

11. Moore KE. The actions of amphetamine on neurotransmitters: a brief review. Biol Psychiatry. 1977;12(3):451–462. [PubMed] [Google Scholar]

12. Pehek AE. Comparison of effects of Haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum. J Pharmacol Exp Therapeut. 1999;289(1):14–23. [PubMed] [Google Scholar]

13. Nakahra T, Kurokit, Hashimoto K, et al. Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain. Neuroreport. 2000;11(3):551–555. [PubMed] [Google Scholar]

14. Kargieman L, Santana N, Mengod G, et al. NMDA antagonist and antipsychotic actions in cortico-subcortical circuits. Neurotox Res. 2008;14(2-3):129–140. [PubMed] [Google Scholar]

15. Volkow ND, Wang G-J, Fowler JS, et al. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am J Psychiatry. 1997;154:50–55. [PubMed] [Google Scholar]

16. Botly L, Burton CL, Rizos Z, Fletcher PJ. Characterization of methylphenidate self-adminstration and reinstatement in the rat. Psychopharmacology. 2008;199:55–56. [PubMed] [Google Scholar]

17. Owen R, Owen F, Poulter M, Crow TJ. Dopamine D2 receptors in substantia nigra in schizophrenia. Brain Res. 1994;299(1):152–154. [PubMed] [Google Scholar]

18. Fehr C, Yakushev I, Hohmann N, et al. Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry. 2008;165:507–514. [PubMed] [Google Scholar]

19. Laurelle M, Abi-Dargham A, van Dyck H, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995;36:1182–1190. [PubMed] [Google Scholar]

20. Leite JV, Guimarães FS, Moreira FA. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol. 2008;578(2-3):222–227. [PubMed] [Google Scholar]

21. Rappley M. Attention deficit-hyperactivity disorder. N Engl J Med. 2005;352:2. [PubMed] [Google Scholar]

22. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14(3):372–394. [PubMed] [Google Scholar]

23. Werry JS, Aman MG. Methylphenidate and haloperidol in children. Effects on attention, memory, and activity. Arch Gen Psychiatry. 1975;32(6):790–795. [PubMed] [Google Scholar]

24. Gittelman-Klein R, Klein DF, Katz S, et al. Comparative effects of methylphenidate and thioridazine in hyperkinetic children. Arch Gen Psychiatry. 1976;33(10):1217–1231. [PubMed] [Google Scholar]

25. Greenberg LM, Deem MA, McMahon S. Effects of dextroamphetamine, chlorpromazine, and hydroxyzine on behavior and performance in hyperactive children. Am J Psychiatry. 1972;129(5):532–539. [PubMed] [Google Scholar]

26. Biederman J, Hammerness P, Doyle R. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatr Dis Treat. 2008;4(1):203–207. [PMC free article] [PubMed] [Google Scholar]

27. Findling RL, Short EJ, Leskovec T, et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18(4):347–354. [PubMed] [Google Scholar]

28. Gualtieri CT, Hicks RE. Stimulants and neuroleptics in hyperactive children (letter) J Am Acad Child Psychiatry. 1985;24:363–364. [PubMed] [Google Scholar]

29. Weizman A, Weitz R, Szekely GA, et al. Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity. J Am Acad Child Psychiatry. 1984;23(3):295–298. [PubMed] [Google Scholar]

30. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921. [PubMed] [Google Scholar]

31. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69(Suppl 4):9–14. [PubMed] [Google Scholar]

32. Pandina GJ, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2006;16(4):379–392. [PubMed] [Google Scholar]

33. Gadow KD, Nolan EE, Sverd J, et al. Methylphenidate in aggressive-hyperactive boys: effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiatry. 1990;29(5):710–718. [PubMed] [Google Scholar]

34. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41:253–261. [PubMed] [Google Scholar]

35. Allen RP, Safer D, Covi L. Effects of psychostimulants on aggression. J Nerv Ment Dis. 1975;160:138–145. [PubMed] [Google Scholar]

36. Sharp B. CMAP ADHD and comorbid aggression algorithm: letter to the editor. ACAP. 2007;46(1):1–3. [PubMed] [Google Scholar]

37. Beller B, Zimerman B, Williams M, et al. DSM-IV mania symptoms in a prepubertal and early adolescent bipolar disorder phenotype compared to attention-deficit hyperactive and normal controls. J Am Acad Child Adolesc Psychiatry. 2002;12(1):11–25. [PubMed] [Google Scholar]

38. Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008;69(12):1928–1936. [PubMed] [Google Scholar]

39. Shajahan P, Taylor M. The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice. J Psychopharmacol. 2010;24(4):565–572. Epub 2009 Jan 22. [PubMed] [Google Scholar]

40. Sajatovic M. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Curr Psychiatry Rep. 2003;5:320–326. [PubMed] [Google Scholar]

41. Hardy SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother. 2009;7(1):34–59. [PMC free article] [PubMed] [Google Scholar]

42. Huang CC, Shiah IS, Chen HK, et al. Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression. Clin Neuropharmacol. 2008;31(4):245–247. [PubMed] [Google Scholar]

43. Nandagopal JJ, DelBello MP, Kowatch R. Pharmacologic treatment of pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2009;18(2):455–469. [PubMed] [Google Scholar]

44. Chang KD. The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry. 2008;69(Suppl 4):4–8. [PubMed] [Google Scholar]

45. Levin A. Kids with bipolar + ADHD respond to added stimulant. Psychiatr News. 2005;40(2):42. [Google Scholar]

46. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull. 2008;41(4):37–47. [PubMed] [Google Scholar]

47. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004;6(5):416–420. [PubMed] [Google Scholar]

48. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(7):1149–1152. [PubMed] [Google Scholar]

49. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196–204. [PubMed] [Google Scholar]

50. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14(2):243–254. [PubMed] [Google Scholar]

51. Hollis CP, Thompson A. Acute dyskinesia on starting methylphenidate after risperidone withdrawal. Pediatr Neurol. 2007;37(4):287–288. [PubMed] [Google Scholar]

52. Connor DF, Benjamin S, Ozbayrak KR. Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1490–1494. [PubMed] [Google Scholar]

53. Benjamin E, Salek S. Stimulant-atypical antipsychotic interaction and acute dystonia. J Am Acad Child Adolesc Psychiatry. 2005;44(6):510–512. [PubMed] [Google Scholar]

54. Sabuncuoglu O. Risperidone-to-methylphenidate switch reaction in children: three cases. J Psychopharmacol. 2009;22(6):699. [PubMed] [Google Scholar]

55. Seeman P, Niznik HB, Guan H-C, et al. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Nat Acad Sci USA. 1989;86:10156–10160. [PMC free article] [PubMed] [Google Scholar]

56. Volkow N, Swanson J. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry. 2003;160:1909–1918. [PubMed] [Google Scholar]

57. Sikström S, Söderlund G. Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder. Psychol Rev. 2007;114(4):1047–1075. [PubMed] [Google Scholar]

58. Goto Y, Otani S, Grace AA. The yin and yang of dopamine release: a new perspective. Neuropharmacology. 2007;53(5):583–587. [PMC free article] [PubMed] [Google Scholar]

59. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41(1):1–24. [PubMed] [Google Scholar]

60. Braun AR, Laruelle M, Mouradian MM. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J Neur Transmis. 1997;104:4–5. [PubMed] [Google Scholar]

61. Gianutsos G, Drawbaugh RB, Hynes MD, Lal H. Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci. 1974;14:887–898. [PubMed] [Google Scholar]

62. Samaha A, Seeman P, Steward J, et al. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27(11):2979–2986. [PMC free article] [PubMed] [Google Scholar]

How Lurasidone Works For ADHD, Anxiety, and Other Mental Disorders

How Lurasidone Works For ADHD, Anxiety, and Other Mental Disorders

  • Post author: